Wetherby Asset Management Inc Novo Cure LTD Transaction History

Wetherby Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$67.99 - $89.57 $2,447 - $3,224	-36 Reduced 1.22%	2,907 $221,000
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $13,923 - $22,115	246 Added 9.12%	2,943 $205,000
Q1 2022 May 16, 2022	SELL	$60.15 - $84.52 $11,428 - $16,058	-190 Reduced 6.58%	2,697 $223,000
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $12,913 - $20,982	172 Added 6.34%	2,887 $217,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $11,965 - $20,038	-103 Reduced 3.66%	2,715 $315,000
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $47,726 - $82,562	366 Added 14.93%	2,818 $625,000
Q1 2021 May 14, 2021	SELL	$124.11 - $190.17 $24,077 - $36,892	-194 Reduced 7.33%	2,452 $324,000
Q4 2020 Feb 11, 2021	BUY	$112.16 - $174.14 $285,559 - $443,360	2,546 Added 2546.0%	2,646 $458,000
Q3 2020 Dec 16, 2020	SELL	$58.05 - $111.31 $119,466 - $229,075	-2,058 Reduced 95.37%	100 $11,000
Q3 2020 Dec 16, 2020	SELL	$58.05 - $111.31 $22,349 - $42,854	-385 Reduced 15.14%	2,158 $240,000
Q3 2020 Nov 13, 2020	BUY	$58.05 - $111.31 $147,621 - $283,061	2,543 New	2,543 $283,000

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.86B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.